首页> 外文期刊>International journal of infectious diseases : >Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months
【24h】

Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months

机译:对分别于2、4、6个月大的健康婴儿接种DTPw-HBV和Hib联合疫苗与分别接种的DTPw-HBV和Hib疫苗的免疫原性和反应原性,在18个月时加强免疫

获取原文
           

摘要

Objectives: To determine the immunogenicity and reactogenicity of a combined DTPw-HBV/Hib vaccine, in comparison with DTPw-HBV and Hib vaccines given as separate concomitant injections. Methods: In an open, randomized study, healthy infants were injected with either DTPw-HBV/Hib vaccine or separate DTPw-HBV and Hib vaccines at 2,4 and 6 months of age, with a booster at 18 months. Results: Both vaccination regimens were immunogenic, with seropositivity rates of 100% after the booster vaccination for all vaccine components. Even as early as 2 months after the second dose of the primary vaccination, most patients had seroprotective antibody titers, the proportion of seropositive subjects approaching 100% for tetanus, hepatitis B, and Hib. Post-primary and post-booster geometric mean titers (GMTs) were well above seroprotective thresholds for each vaccine antigen in both groups, with no clinically relevant differences in the groups. The separate and combined administrations showed comparable reactogenicity profiles, and neither showed a significant increase in reactogenicity with successive doses. Conclusions: The results of this study support the combination of Hib and DTPw-HBV vaccination in routine infant immunization at 2,4 and 6 months of age with a booster at 18 months. Maximum benefit is obtained from compliance with the full course, but substantial benefit is likely to be achieved even in partially compliant patients, provided they receive at least two doses. Furthermore, these results demonstrate the tolerability of a fourth (booster) administration, where the addition of the Hib vaccine to DTPw-HBV did not lead to an increase in the overall reactogenicity.
机译:目的:与单独注射的DTPw-HBV和Hib疫苗相比,确定DTPw-HBV / Hib联合疫苗的免疫原性和反应原性。方法:在一项开放,随机的研究中,健康婴儿在2,4和6个月大时分别注射DTPw-HBV / Hib疫苗或单独的DTPw-HBV和Hib疫苗,并在18个月时加强免疫。结果:两种疫苗接种方案均具有免疫原性,所有疫苗成分的加强疫苗接种后血清阳性率为100%。即使在第二次初次接种疫苗后的2个月之内,大多数患者仍具有血清保护性抗体滴度,破伤风,乙型肝炎和Hib血清反应阳性受试者的比例接近100%。在两组中,初次免疫后和加强免疫后的几何平均滴度(GMT)均远高于每种疫苗抗原的血清保护阈值,各组之间在临床上无相关差异。分开和联合给药显示出可比较的反应原性,并且连续给药均未显示出显着的反应原性增加。结论:这项研究的结果支持在2、4和6个月大的婴儿常规免疫中采用Hib和DTPw-HBV疫苗联合接种,在18个月时加强免疫。全程服从可以获得最大的益处,但是即使部分服从的患者接受至少两次剂量,也有可能获得实质性的益处。此外,这些结果证明了第四次(加强)给药的耐受性,其中在DTPw-HBV中添加Hib疫苗不会导致总体反应原性增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号